Research workbench
crystal structure of anti-HCV monoclonal antibody 19D9D6
Analyse crystal structure of anti-HCV monoclonal antibody 19D9D6 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 1NLB
- Type
- protein
- Length
- 438 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v2 / PDB Bank
- Contract
- 0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
- Owner
- 0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
- Resolution
- 1.6
- Source
- Mus musculus
- Molecule
- antibody 19D9D6 light chain; antibody 19D9D6 heavy chain
- Pockets
- 4 · best druggability 0.55
Structure
x-ray diffraction · resolution 1.6 · 2 distinct chains · 8% helix, 52% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| L | antibody 19D9D6 light chain | protein | 220 | 8% helix, 52% strand | — |
| H | antibody 19D9D6 heavy chain | protein | 218 | 8% helix, 53% strand | — |
Pockets
4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 352 | 0.55 | 0.74 | 59 | empty |
| 2 | 124 | 0.51 | 0.80 | 20 | empty |
| 3 | 84 | 0.31 | 0.73 | 22 | empty |
| 4 | 61 | 0.28 | 0.74 | 18 | empty |
Interfaces
1 interface between chains.
- L–H · 1871 Ų buried · 16 hydrogen bonds · protein-protein
Modifications
Observed in the structure: 4 disulfide (disulfide).
Compared structures
- 1NLB · Crystal structure of anti-HCV monoclonal antibody 19D9D6 · the same entry in another collection · chain H against H, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Elsewhere: RCSB PDB 1NLB · PDBe 1NLB
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.